AXSM — Axsome Therapeutics Balance Sheet
0.000.00%
- $7.47bn
- $7.36bn
- $385.69m
Annual balance sheet for Axsome Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 184 | 86.5 | 201 | 386 | 315 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | 37.7 | 94.8 | 142 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 184 | 86.5 | 246 | 504 | 485 |
| Net Property, Plant And Equipment | 1.79 | 0.944 | 1.14 | 7.62 | 5.97 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 186 | 87.8 | 331 | 588 | 568 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 23.4 | 23.1 | 96.6 | 139 | 230 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 72.3 | 72.2 | 222 | 397 | 511 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 114 | 15.6 | 110 | 191 | 57 |
| Total Liabilities & Shareholders' Equity | 186 | 87.8 | 331 | 588 | 568 |
| Total Common Shares Outstanding |